|
|
|
|
| LEADER |
02545nam a22003855i 4500 |
| 001 |
978-3-7643-8679-5 |
| 005 |
20191027181754.0 |
| 007 |
cr nn 008mamaa |
| 008 |
100301s2009 sz | s |||| 0|eng d |
| 020 |
|
|
|a 9783764386795
|
| 024 |
7 |
|
|a 10.1007/978-3-7643-8679-5
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a PEGylated Protein Drugs: Basic Science and Clinical Applications
|c edited by Francesco M. Veronese.
|
| 250 |
|
|
|a 1st ed. 2009.
|
| 260 |
# |
# |
|a Basel :
|b Birkhäuser Basel :
|b Imprint: Birkhäuser,
|c 2009.
|
| 300 |
|
|
|a IX, 290 p.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Milestones in Drug Therapy,
|
| 505 |
0 |
|
|a Preface PEGylated protein conjugates: A new class of therapeutics for the 21st century -- Protein PEGylation, basic science and biological applications -- Reactive PEGs for protein conjugation -- Rebridging disulphides: site-specific PEGylation by sequential bis-alkylation -- Enzymatic techniques for PEGylation of biopharmaceuticals -- The site-specific TGase-mediated PEGylation of proteins occurs at flexible sites -- Protein conjugates purification and characterization -- PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals -- The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol) -- Pegfilgrastim — designing an improved form of rmetHuG-CSF -- PEGylation of human growth hormone: strategies and properties -- PEGylated ? interferons: two different strategies to achieve increased efficacy -- Development of PEGylated mammalian urate oxidase as a therapy for patients with refractory gout -- Certolizumab pegol: a PEGylated anti-tumour necrosis factor alpha biological agent -- PEG: a useful technology in anticancer therapy -- Regulatory strategy and approval processes considered for PEG-drug conjugates and other nanomedicines.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
|
0 |
|a Immunology.
|
| 650 |
|
0 |
|a Biotechnology.
|
| 650 |
|
0 |
|a Medical biochemistry.
|
| 650 |
|
0 |
|a Medicinal chemistry.
|
| 650 |
1 |
4 |
|a Pharmacology/Toxicology.
|
| 650 |
2 |
4 |
|a Immunology.
|
| 650 |
2 |
4 |
|a Biotechnology.
|
| 650 |
2 |
4 |
|a Medical Biochemistry.
|
| 650 |
2 |
4 |
|a Medicinal Chemistry.
|
| 700 |
1 |
|
|a Veronese, Francesco M.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-7643-8679-5
|